| Identification | Back Directory | [Name]
1-phenyl-2-(pyridin-2-yl)ethanamine | [CAS]
61890-25-3 | [Synonyms]
(Rac)-Lanicemine
rac-Lanicemine 2HCl
1-Phenyl-2-(2-pyridinyl)ethanamine
1-phenyl-2-(pyridin-2-yl)ethanamine | [Molecular Formula]
C13H14N2 | [MDL Number]
MFCD11188752 | [MOL File]
61890-25-3.mol | [Molecular Weight]
198.26 |
| Chemical Properties | Back Directory | [Boiling point ]
160 °C(Press: 2 Torr) | [density ]
1.097±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mg/mL (504.39 mM) | [form ]
Liquid | [pka]
8.29±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
(Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1]. | [in vivo]
Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1].
Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 3, 10 or 30?mg/kg | | Administration: | Intraperitoneal | | Result: | Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity. |
| [IC 50]
NMDA Receptor | [References]
[1] Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. DOI:10.1038/mp.2013.130 |
|
| Company Name: |
Tcichem, Inc.
|
| Telephone: |
13918644899 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList19113/0_EN.htm |
|